ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Bioventus Inc

Bioventus Inc (BVS)

6.90
0.35
(5.34%)
Closed July 16 4:00PM
6.89
-0.01
(-0.14%)
After Hours: 7:59PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
6.90
Bid
6.72
Ask
7.00
Volume
424,252
6.43 Day's Range 6.94
2.8214 52 Week Range 7.0399
Market Cap
Previous Close
6.55
Open
6.56
Last Trade
40
@
7
Last Trade Time
Financial Volume
$ 2,846,539
VWAP
6.7095
Average Volume (3m)
427,536
Shares Outstanding
79,614,354
Dividend Yield
-
PE Ratio
-3.51
Earnings Per Share (EPS)
-1.96
Revenue
512.35M
Net Profit
-156.23M

About Bioventus Inc

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, in... Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
1970
Bioventus Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker BVS. The last closing price for Bioventus was $6.55. Over the last year, Bioventus shares have traded in a share price range of $ 2.8214 to $ 7.0399.

Bioventus currently has 79,614,354 shares outstanding. The market capitalization of Bioventus is $521.47 million. Bioventus has a price to earnings ratio (PE ratio) of -3.51.

BVS Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.0217.34693877555.886.945.734986376.29007715CS
40.711.29032258066.26.945.285698255.8708214CS
122.3504.67.03993.94275365.85264128CS
261.8536.63366336635.057.03993.92715525.59822744CS
523.3393.27731092443.577.03992.82142488294.84014438CS
156-9.51-57.952468007316.4117.640.79993902195.02766541CS
260-8.2-54.304635761615.119.94090.79993674915.77010134CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AMIXAutonomix Medical Inc
$ 1.3701
(121.70%)
154.81M
SHOTWSafety Shot Inc
$ 0.41
(115.79%)
7.56k
DATSDatChat Inc
$ 1.89
(81.73%)
54.75M
CYNCYNGN Inc
$ 9.18
(53.77%)
17.79M
SCNIScinai Immunotherapeutics Ltd
$ 5.80
(42.86%)
29.37M
ASLNASLAN Pharmaceuticals Ltd
$ 1.36
(-46.67%)
1.16M
KZIAKazia Therapeutics Ltd
$ 0.5593
(-37.56%)
15.34M
LCFYLocafy Ltd
$ 3.5597
(-36.32%)
584.38k
NAASNaaS Technology Inc
$ 2.82
(-33.02%)
1.94M
ZENVZenvia Inc
$ 1.67
(-26.75%)
658.26k
FFIEFaraday Future Intelligent Electric Inc
$ 0.5152
(22.09%)
217.92M
NVDANVIDIA Corporation
$ 128.44
(-0.62%)
208.32M
SQQQProShares UltraPro Short QQQ
$ 7.46
(-0.67%)
155.14M
AMIXAutonomix Medical Inc
$ 1.3701
(121.70%)
154.81M
TSLATesla Inc
$ 252.64
(1.78%)
147.31M

BVS Discussion

View Posts
Monksdream Monksdream 1 month ago
BVS under $10
👍️0
tw0122 tw0122 2 months ago
Durolane like it .. older news ..Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

Source: GlobeNewswire Inc.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract.
OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as DUROLANE, help manage knee OA pain.

“We are pleased DUROLANE is among the preferred options available to both Aetna™ Medicare Advantage members and physicians,” said Anthony Doyle, General Manager, Pain Treatments and Restorative Therapies for Bioventus. “Both now have access to a safe HA product that is proven to provide relief from knee OA pain.”

About Bioventus

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

👍️0
TheFinalCD TheFinalCD 2 months ago
$BVS - Bioventus GAAP EPS of -$0.07 beats by $0.18, revenue of $129.45M beats by $11.07M https://t.co/IGk1Zy2r5X— Seeking Alpha Market News (@MarketCurrents) May 7, 2024
👍️0
Monksdream Monksdream 3 months ago
BVS under $5

👍️0